High-Dose Trivalent Influenza Vaccine or Standard-Dose Quadrivalent Inactivated Influenza Vaccine in Treating Adult Stem Cell Transplant Recipients

Inclusion Criteria

• Allogeneic HSCT recipients who are 3-23 months post-transplant
• Available for duration of study
• Patients with stable graft versus host disease (GVHD) for at least 4 weeks will be eligible (stable is defined as no major change in systemic immunosuppressive therapy for worsening GVHD; adjustment of actual dose to obtain a stable target level is acceptable)
• Can be reached by telephone and/or electronic communication
• Subjects must have a platelet count of >= 30,000 to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= 30,000 within 72 hours prior to their immunization, or platelet count >= 75,000 without transfusion documented within 30 days for subjects < 12 months post-transplant and within 90 days for subjects 12-23 months post-transplant
• FOR REPEATERS: Available for duration of study
• FOR REPEATERS: Can be reached by telephone and/or electronic communication
• FOR REPEATERS: Patients with stable GVHD for at least 4 weeks will be eligible (stable is defined as no major change in systemic immunosuppressive therapy for worsening GVHD; adjustment of actual dose to obtain a stable target level is acceptable)
• FOR REPEATERS: Subjects must have a platelet count of >= 30,000 to receive the immunizations; patients requiring platelet transfusions are eligible to enroll and must have a platelet count >= 30,000 within 72 hours prior to their immunization, or platelet count >= 75,000 without transfusion documented within 30 days for subjects < 12 months post-transplant and within 90 days for subjects 12-23 months post-transplant.

Exclusion Criteria

• History of hypersensitivity to previous influenza vaccination or severe hypersensitivity to eggs/egg protein
• History of Guillain-Barre syndrome
• Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerism is permitted)
• History of receiving current seasonal influenza vaccine post-transplant
• Pregnant female
• History of proven influenza disease after September 1, 2018 prior to enrollment
• Non-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT) recipients
• History of known active infection with human immunodeficiency virus (HIV)
• History of cirrhosis
• History of known latex hypersensitivity
• Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
• Receipt of intravenous immunoglobulin therapy (IVIG)/subcutaneous immunoglobulin therapy (SCIG) < 28 days prior to vaccination
• FOR REPEATERS: Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerism is permitted)
• FOR REPEATERS: History of receiving current seasonal influenza vaccine post-transplant
• FOR REPEATERS: Pregnant female
• FOR REPEATERS: History of proven influenza disease after September 1, 2019 prior to enrollment
• FOR REPEATERS: History of known active infection with HIV
• FOR REPEATERS: History of cirrhosis
• FOR REPEATERS: Subjects who have received stem cell boost or delayed donor lymphocyte infusion within 90 days of enrollment, including day of enrollment
• FOR REPEATERS: Receipt of IVIG/SCIG < 28 days prior to calendar day of vaccination